Skip to content

Vanda Pharmaceuticals Inc.

VNDA

CIK 0001347178

← back to feed
Revenue (TTM)
$210.61M
+8.7% YoY Q1 Apr 2026
Net Income (TTM)
−$127.85M
−1,066.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.16
−1,033.3% YoY Q1 Apr 2026
Gross Margin
28.9%
Q1 Apr 2026
Operating Margin
-76.5%
Q1 Apr 2026
Net Margin
-60.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$44.71M
Q1 Apr 2026
Cash
$54.03M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
60.14M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings